. Author manuscript; available in PMC: 2010 Jul 1.

Published in final edited form as: Gastrointest Endosc. 2009 May 24;70(1):96–10924. doi: 10.1016/j.gie.2008.08.040

Table 3.

Results from cost-effectiveness analysis

Strategy	CRC cases/100,000 from age 40 to age 100	CRC deaths/100,000 from age 40 to age 100^*	Life-expectancy at age 40^†	Lifetime per person cost for CRC screening and treatment after age 40^†	ICER^†
No screening	5712	2027	22.3929	$ 1,663	Base Case
Uniform 10-yearly cspy	3026	794	22.4340	$ 2,310	Dominated
Uniform 8-yearly cspy	2901	751	22.4362	$ 2,349	$ 15,565
Individualized	2882	739	22.4363	$ 2,340	$ 15,565

ICER: Incremental Cost-Effectiveness Ratio

Including procedural deaths from colonoscopy complications

^†

3% discounted